商业财经付费内容
This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
MarketWatch作者：Jaimy Lee2026年9月22日正文已收录本站
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.